ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,998,991, entitled “Neurotherapeutic treatment for sexual dysfunction.”
